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The  efﬁcacy  of  the  novel  isoxazoline,  sarolaner  (SimparicaTM) was  investigated  in dogs  with  clinical  signs
consistent  with  sarcoptic  mange  and  harbouring  natural  infestations  of  Sarcoptes  scabiei.  One  placebo-
controlled  laboratory  study  and  one  multi-centred  ﬁeld  study  with  a commercial  comparator  containing
imidacloprid/moxidectin  (Advocate® spot-on)  were  conducted.  Oral  or topical  treatments  were  admin-
istered on Days  0 and  30.  Up to  10 skin  scrapings  were  taken  for  the  assessment  of  S.  scabiei  infestations
from each  dog  before  treatment  and  on Days  14, 30,  44  and  60 in the  laboratory  study,  and  on Days  30
and  60  in  the  ﬁeld  study.  In the  laboratory  study,  efﬁcacy  was calculated  based  on  the percent  reduction
of  mean  live  mite  counts  compared  to  the placebo  group.  In the ﬁeld  study  parasitological  cure rate  (%
dogs  free  of  mites)  was  determined  and  non-inferiority  of sarolaner  to the  control  product  was  assessed.
In  the laboratory  study  44 mixed  breed  dogs  were  enrolled  in  four batches.  Due  to  decreasing  mite
counts  in the placebo  treated  dogs,  immunosuppression  with  dexamethasone  (0.4 mg/kg  three  times
per  week  for  two weeks)  was  initiated  in  all dogs  on study  at that  time  (n  =  6)  and  those  subsequently
enrolled (n =  14).  In  the  ﬁeld  study,  dogs  were  enrolled  in  a 2:1 ratio  (sarolaner:comparator);  79  dogs
were assessed  for efﬁcacy  and  safety,  and  an  additional  45 dogs  were  assessed  for safety  only.  There  were
no treatment  related  adverse  events  in  either  study.
In  the  laboratory  study,  no  mites  were  found  on  any  sarolaner-treated  dogs  14  days  after  the  ﬁrst
treatment  except  for one  dog  that  had  a  single  mite  on  Day  44. In  the  ﬁeld study,  the  parasitological  cure
rate was  88.7%  and  100%  in  the  sarolaner  group  and  84.6%  and  96.0%  in the imidacloprid/moxidectin
group,  on  Days  30  and  60,  respectively.  Statistical  analysis  showed  that  sarolaner  was  non-inferior  to
imidacloprid/moxidectin  at both  time  points.  The  clinical  signs  of  sarcoptic  mange,  including  hair  loss,
papules,  pruritus,  erythema,  and  scaling/crusting  improved  throughout  the  study.
Sarolaner  was  safe,  achieved  100%  reduction  in  the  numbers  of  S. scabiei  detected  and  resulted  in
marked  improvement  of the  clinical  signs  of sarcoptic  mange  in  dogs  following  two  monthly  oral  admin-
istrations.
© 2016  The  Authors.  Published  by  Elsevier  B.V. This  is  an  open  access  article  under  the  CC  BY-NC-ND. Introduction
Sarcoptes scabiei var. canis is one of the mites most commonly
nfesting dogs worldwide and causes severe pruritus and may  be
ssociated with secondary bacterial pyoderma. Scabies is highly
ontagious and has zoonotic potential (Miller et al., 2013). Diag-
osis is usually based on the presence of clinical signs and the
etection of mites in skin scrapings. Infested dogs show severe pru-
∗ Corresponding author.
E-mail address: csilla.becskei@zoetis.com (C. Becskei).
ttp://dx.doi.org/10.1016/j.vetpar.2016.02.017
304-4017/© 2016 The Authors. Published by Elsevier B.V. This is an open access article 
/).license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
ritus, an erythematous rash and yellowish crusts on the skin (Arlian
et al., 1995). The licenced treatment options for sarcoptic mange are
limited mostly to topical products. Depending on the region, these
may include selamectin and moxidectin/imidacloprid containing
spot-on products, and in some countries amitraz dip. Shampooing
or bathing with medicated or non-medicated products are gener-
ally part of the adjunctive therapy for clinical mange to rehydrate
the skin and treat seborrhoea, but these procedures may  also reduce
the efﬁcacy or shorten the residual activity of topical products.
Extra-label use of macrocyclic lactones such as moxidectin and
ivermectin have been reported to be effective via oral and injectable
routes (Wagner and Wendleberger, 2000; Curtis, 2004) but to be
under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.
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ffective these need to be given at high dose rates (0.2–0.5 mg/kg)
nd intervals of 1–2 weeks, risking potentially severe side effects.
he only oral product approved in some countries for the treatment
f sarcoptic mange is milbemycin oxime, however the need for
very-other-day administration may  not be an affordable or conve-
ient option for most owners. Therefore a proven, convenient and
afe, oral treatment option would provide a signiﬁcant beneﬁt for
he care of sarcoptic mange patients.
Sarolaner (SimparicaTM chewable tablets, Zoetis), the latest
ddition to the isoxazoline class of oral ectoparasiticides is a very
otent insecticide and acaricide (McTier et al., 2016). With its
onthly dosing schedule, sarolaner could provide a very conve-
ient and effective treatment option for dogs suffering from mite
nfestations. A laboratory study was conducted to evaluate the
fﬁcacy of two monthly doses of sarolaner for the treatment of sar-
optic mange in dogs and a multi-centred ﬁeld study in veterinary
atients was conducted to conﬁrm the efﬁcacy and safety of this
reatment and dosing regimen.
. Materials and methods
The laboratory study was a masked, placebo controlled, random-
zed study conducted in South Africa. The ﬁeld study was a masked,
andomized trial that was conducted at veterinary practices in the
K, Spain, Italy, France, Belgium and Hungary and used a positive
ontrol containing imidacloprid and moxidectin (Advocate® Spot
n, Bayer) that is approved for the treatment of sarcoptic mange in
urope. In both studies dogs received two monthly treatments. The
tudies were conducted in compliance with Good Clinical Practice,
VICH guideline GL9, EMEA, 2000). Masking was accomplished by
eparation of functions of study personnel. The person(s) who made
linical observations and conducted parasite counts was masked to
xperimental treatments. All treatments were dispensed by a dedi-
ated dispenser, who was not involved in any other study activities.
he protocol for the laboratory study was approved by the ClinVet
nstitutional Animal Care and Use Committee. Ethical approval for
he ﬁeld study was provided by the Zoetis Ethics Review Assess-
ent team.
.1. Laboratory study
.1.1. Animals
Forty four mixed breed dogs of both sexes, ranging from seven
onths to 11 years of age and weighing 5.3–24.6 kg with natural
. scabiei infestations were enrolled. The dogs had clinical signs of
arcoptic mange and had live S. scabiei (adults, larvae or nymphs)
onﬁrmed in deep skin scrapings at enrolment. Dogs were housed
n individual runs, so that no physical contact was  possible between
hem. Dogs were fed an appropriate maintenance ration of a com-
ercial dry canine feed for the duration of the study. Water was
vailable ad libitum.
.1.2. Experimental design and methods
Dogs were enrolled in four batches (minimum four dogs/batch)
s adequate numbers of animals with clinical signs were conﬁrmed
ositive for scabies mites in skin scrapings. Within batches, dogs
ere randomly allocated to treatment with sarolaner or placebo
ased on pre-treatment mite counts.
The severity of the clinical signs of S. scabiei infestation
erythema, scaling/crusting, papules, pustules, alopecia) were eval-
ated as follows: absent (no signs present); mild (intensity/density
f the clinical sign is low and <25% of the animal’s body is affected);
oderate (clinical sign is of great intensity/density over <25% of the
nimal’s body or is of lesser intensity/density but affects 25–50%
f the body); severe (clinical sign is of great intensity/density and
overs >50% of the animal’s body).sitology 222 (2016) 56–61 57
To count mites, deep skin scrapings were taken from at least
four separate sites on each dog. If no mites were detected in the
ﬁrst four scrapings, additional scrapings were made until live mites
were found or the maximum of ten scrapings was  reached. Selected
scraping sites were those that had the most severe or most likely
evidence of current mite infestation. Scrapings were conducted to
an approximately constant depth (to capillary bleeding) over an
area of approximately 2.5 cm2. The collected material was trans-
ferred to mineral oil on a microscope slide and live S. scabiei mites
(larvae, nymphs and adults) and eggs were counted using 20× mag-
niﬁcation.
Day 0 for each batch of dogs was  the day the ﬁrst study treatment
was given. Prior to treatment each dog was given a detailed physical
exam to ensure suitability for inclusion and all dogs were observed
for general health at least twice daily throughout the study. On
Days 0 and 30, the 22 dogs allocated to treatment with sarolaner
received tablets individually shaved and/or sanded to provide the
target dose of 2 mg/kg. The 22 placebo-treated dogs received a sin-
gle placebo tablet. Dogs were offered their normal ration of food
approximately1 h prior to tablet administration. Dogs were hand
pilled to ensure accurate and complete dosing and observed for
general health and any reaction to treatment approximately 1, 3
and 6 h after treatment.
Deep skin scrapings and mite counts were performed on all dogs
on Days 14, 30, 44 and 60. During the study it was noted that live
mite counts were decreasing in the placebo-treated dogs. As this
apparent self-clearing of mite infestations could interfere with the
determination of efﬁcacy, immunosuppression was  initiated with
intramuscular or subcutaneous dexamethasone (0.4 mg/kg three
times per week for two  weeks, Kortico®, Bayer) of all dogs on study
at that time and for dogs subsequently enrolled. At this time, 12
dogs in each treatment group had already completed the study.
Three dogs in each treatment group were on study having already
received their ﬁrst parasiticide treatment. Therefore these dogs
received their immunosuppressive treatment between study days
0 and 30. Seven dogs in each group were enrolled after the deci-
sion was  made and received immunosuppression before their ﬁrst
parasiticide treatment. Due to the initiation of immunsuppressive
therapy, clinical signs of sarcoptic mange were not evaluated.
2.1.3. Data analysis
The primary variable for analysis was live mite count (adult,
nymph and larvae combined). Assessment of efﬁcacy was  based on
the percent reductions in mean live mite counts relative to placebo
and pre-treatment counts calculated for each time point as follows:
%Efﬁcacy = (Mean Placebo(Pretreatment)-  Mean Treated)
Mean Placebo(Pretreatment)
×  100
The numbers and proportions of dogs that were mite free was
calculated for each time point.
2.2. Field study
2.2.1. Animals
The patient population was  recruited from veterinary practices
located in various geographical and climatic locations in the EU.  One
dog in each household was  allowed to be enrolled as the primary
patient and only that dog received efﬁcacy evaluations. Other dogs
living in the same household as the primary dogs were enrolled
as supplementary patients that were only evaluated for safety and
palatability. The primary dog had to show clinical signs of sarcop-
tic mange and harbour live S. scabiei mites in deep skin scrapings.
Dogs had to be at least 8 weeks of age and weigh at least 1.3 kg.
There were no breed or gender restrictions, but dogs intended for
breeding or that were pregnant or lactating were not eligible for
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nrolment. Dogs with pre-existing conditions under stable veteri-
ary management could be included. Dogs with clinical mange due
o Demodex spp. mites or with existing uncontrolled medical con-
itions that might confound the study were excluded, as were dogs
hat had been treated with products with residual activity against S.
cabiei within 30 days of the start of the study. Dogs came from sin-
le dog households and households with other dogs (up to a total of
ve dogs). The dogs were kept under their normal household con-
itions and thus, lived indoors only, outdoors only, or both indoors
nd outdoors. Each dog was enrolled with the written informed
onsent of the owner.
.2.2. Experimental design and methods
On Day −1 or 0, primary dogs were examined to ensure suitabil-
ty for enrolment (bodyweight, physical examination, skin scraping,
nd clinical sign assessment). Primary dogs were allocated in a ratio
f 2:1 to one of two treatment groups to receive sarolaner or the
ommercial comparator, respectively, in a randomized block design
ith one-way treatment structure replicated in multiple clinics.
upplementary dogs received the same treatment as the primary
og.
All treatments were dispensed according to a randomization
lan that was provided for each clinic before the start of the study.
reatment dispensing was based upon body weights recorded
n Days 0 and 30, and treatments were administered by the
wner in the home environment on these Days. The Owners
ere not masked to treatment allocation. Animals were dosed
ith the appropriate strength sarolaner ﬂavored, chewable tablet
SimparicaTM) to provide the recommended minimum dose of
 mg/kg (range 2–4 mg/kg). The voluntary acceptance and con-
umption of sarolaner tablets within one minute after offering
as evaluated by the Owner at each administration. The imi-
acloprid/moxidectin spot-on (Advocate®) was applied topically
ccording to its label directions to deliver 10–25 mg/kg imidaclo-
rid and 2.5–6.25 mg/kg moxidectin.
At clinic visits on Days 14, 30, and 60, primary dogs received
 physical exam and were evaluated for the clinical signs of sar-
optic mange. Skin scrapings were conducted on Days 30 and 60.
upplementary dogs were given physical exams only at these clinic
isits. The severity of clinical signs of sarcoptic mange (including
ruritus, erythema, scaling/crusting, papules and hair loss) were
valuated on a four grade scale as absent, mild, moderate or severe.
o assess presence/absence of mites, deep skin scrapings were con-
ucted as described for the laboratory study. Skin scraping was
epeated until a live mite was found or a maximum of 10 sites had
een scraped. All dogs (primary and supplementary) that received
t least one treatment were included in the safety assessment. All
bnormal health events observed during the physical examinations
y the veterinarian or observed by the owner between visits, were
ecorded.
.2.3. Data analysis
Only primary dogs were included in the efﬁcacy analysis. The
nimal (primary dog per household) was the experimental unit. The
rimary efﬁcacy endpoint was the parasitological cure rate, which
as deﬁned as the percent of dogs for which no live mites were
ound in the skin scrapings. The secondary efﬁcacy endpoint was
he frequency distribution of the skin lesion severity grades at each
ost-treatment time point. Dogs that received concomitant medi-
ations that could have potentially affected the clinical signs of mite
nfestation were excluded from the analysis of skin lesion assess-
ent. For the parasitological cure rate, non-inferiority of sarolaner
o the positive control product was assessed at each time point
sing a margin of 15% at the one-sided  = 0.025 signiﬁcance level.sitology 222 (2016) 56–61
3. Results
3.1. Laboratory study
3.1.1. Efﬁcacy
On Days 14, 30, 44, and 60, mite counts from 21, 20, 19, and 18
placebo-treated dogs, and from 22, 22, 20, and 20 sarolaner-treated
dogs were included in the efﬁcacy evaluation.
For all dogs (non-immunosuppressed and immunosuppressed),
the efﬁcacy based on arithmetic means for sarolaner-treated dogs
compared to placebo-treated dogs or relative to the pre-treatment
mean was  >99% at all post treatment evaluations (Table 1). Arith-
metic mean live mite counts were increased in the placebo group
relative to pre-treatment at all post treatment evaluations except
Day 60, when there was an 82.8% reduction.
Seventy seven percent (77%) of sarolaner-treated dogs were free
of mites on Day 14, 100% were free of mites on Days 30 and 60, and
only one live mite was found on a single sarolaner-treated dog on
Day 44 (Table 2). The percentages of dogs with live mites in the
placebo group on Days 14, 30, 44 and 60 were 52.4, 35.0%, 36.8
and 38.9%, respectively. Only two  of 11 (18%) placebo-treated dogs
that did not receive any immunosuppression harbored live mites
on Day 60. In contrast, one of three dogs (33%) that were started on
immunosuppression before Day 30, and all four dogs (100%) that
were immunosuppressed for the entire study had live mites on Day
60.
3.1.2. Health observations
There were no adverse health events related to treatment with
sarolaner noted in the study. In the placebo group, three dogs died
during the study, two  from canine ehrlichiosis and one due to
glomerulonephritis. One additional, placebo dog was withdrawn
due to a transmissible venereal tumour. Two dogs were removed
from the sarolaner group when they were identiﬁed as pregnant
during the study.
3.2. Field study
3.2.1. Animals
A total of 79 primary dogs (53 in the sarolaner group and 26 in
the imidacloprid/moxidectin group) and 45 supplementary dogs
(26 in the sarolaner group and 19 in the imidacloprid/moxidectin
group) were enrolled and treated. All enrolled dogs completed the
study. One dog in the imidacloprid/moxidectin group was  inadver-
tently under-dosed at the second administration, therefore the Day
60 mite counts from this dog were excluded from the data analysis.
The mean age at enrolment was 4.2 years in the sarolaner
group and 4.1 years in the imidacloprid/moxidectin group. In the
sarolaner group, 48.1% of the dogs were purebreeds and 51.9% were
mixed breeds, while in the imidacloprid/moxidectin group 31.1%
were purebreeds and 68.9% were mixed breeds. In the sarolaner
group, 57% of the dogs were females and 43% were males, while in
the imidacloprid/moxidectin group 60% were females and 40% were
males. At enrolment the mean body weight was  21.7 and 18.1 kg
in the sarolaner and the imidacloprid/moxidectin treated groups,
respectively.
3.2.2. Efﬁcacy
Live mites were found in six sarolaner-treated dogs (11.3%) on
Day 30, while on Day 60, no live mites were detected on any dog
in the sarolaner group (Table 3). In the moxidectin/imidacloprid-
treated group four dogs (15.4%) had live mites present in the
skin scrapings on Day 30 and one dog (4.0%) on Day 60. Thus,
the parasitological cure rate on Days 30 and 60 was 88.7%
and 100% in the sarolaner group, and 84.6% and 96.0% in the
moxidectin/imidacloprid group. The parasitological cure rate for
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Table  1
Efﬁcacy against Sarcoptes scabiei in the laboratory study: number of dogs, arithmetic mean live mite counts (nymphs, larvae and adults), ranges, percent reductions relative
to  pre-treatment count, and efﬁcacy relative to placebo for dogs dosed with sarolaner chewable tablets administered orally once a month for two months.
Study day Treatment group Number of dogsa Mite counts Reduction/Efﬁcacya (%)
Arithmetic mean Range Versus pre-treatment Versus placebo
0 Placebo 22 28.1 1–234 – –
Sarolaner 22 82.9 1–1577 – –
14  Placebo 21 61.4 0–942 0.0 –
Sarolaner 22 0.5 0–5 99.4 99.2
30  Placebo 20 28.6 0–463 0.0 –
Sarolaner 22 0.0 0–0 100 100
44  Placebo 19 74.3 0–1263 0.0 –
Sarolaner 20 0.1 0–1 99.9 99.9
60  Placebo 18 4.8 0–30 82.8 –
Sarolaner 20 0.0 0–0 100 100
a 12 dogs in each treatment group never received immunosuppression; three dogs in each treatment group received immunosuppression between Day 0 and 30; in seven
dogs  in each group immunosuppression started before Day 0.
Table 2
Efﬁcacy against Sarcoptes scabiei in the laboratory study: numbers and proportions of dogs with live mites or no live mites detected in skin scrapings for dogs dosed with
placebo  or sarolaner chewable tablets administered orally once a month for two  months.
Study day Treatment group Number of dogs* No live mites Live mites
Number % Number %
0 Placebo 22 0 0.0 22 100
Sarolaner 22 0 0.0 22 100
14 Placebo 21 10 47.6 11 52.4
Sarolaner 22 17 77.3 5 22.7
30 Placebo 20 13 65.0 7 35.0
Sarolaner 22 22 100 0 0.0
44 Placebo 19 12 63.2 7 36.8
Sarolaner 20 19 95.0 1 5.0
60 Placebo 18 11 61.1 7 38.9
Sarolaner 20 20 100 0 0.0
* 12 dogs in each treatment group never received immunosuppression; three dogs in each treatment group received immunosuppression between Day 0 and 30; in seven
dogs  in each group immunosuppression started before Day 0.
Table 3
Efﬁcacy against Sarcoptes scabiei in the ﬁeld study: Number of dogs with no live mites, parasitological cure rates, conﬁdence intervals and non-inferiority for dogs presented
as  veterinary patients and dosed with sarolaner chewable tablets administered orally or imidacloprid/moxidectin applied topically once a month for two months.
Study day Treatment Number of dogs Parasitological cure ratea Lower 97.5% CI Non-inferior?b
Total No live mites
30 ± 5 Sarolaner 53 47 88.7
Imidacloprid/moxidecin 26 22 84.6 −0.109 YES
60  ± 5 Sarolaner 53 53 100
Imidacloprid/moxidecin 25 24 96.0 −0.029 YES
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b Parasitological cure rate of sarolaner determined to be non-inferior to imidiclop
arolaner was non-inferior to moxidectin/imidacloprid at both time
oints (Table 3).
At enrolment, the majority of the dogs in both groups had alope-
ia, papules, pruritus, erythema, and scaling/crusting (Table 4),
nd these signs were graded as moderate to severe in at least
0% of the dogs. These clinical signs of sarcoptic mange improved
arkedly throughout the study in both groups. At study comple-
ion only 25.5%, 2.0%, 2.0%, 5.9% and 11.8% of the dogs had hair
oss, papules, pruritus, erythema, or scaling/crusting, respectively
n the sarolaner group, while 16.7%, 0.0%, 12.5%, 8.3% and 12.5%
f the dogs had these signs in the moxidectin/imidacloprid group
Table 4). Skin lesions that were present at study completion were
ostly mild in nature. Skin lesions of moderate severity were
nly observed in ﬁve dogs at study completion of which mod-
rate alopecia was reported in one dog in each group, moderatehaving no live mites in the skin scrapings on the respective study day.
oxidectin if the one-sided exact lower 97.5% CI was greater than −0.15.
scaling/crusting in one dog in the sarolaner group, and moderate
erythema and pruritus in one dog in each group at study com-
pletion. One dog in the moxidectin/imidacloprid group had severe
pruritus at study completion and live mites were present on skin
scraping.
3.3. Safety
There were no adverse reactions to treatment with sarolaner.
Abnormal health events were reported in 10 dogs, seven in the
sarolaner-treated group and three in the moxidectin/imidacloprid-
treated group. In the sarolaner group, there were four dogs
with various dermatologic abnormalities (bacterial cellulitis, bite
wounds and pyotraumatic dermatitis), all of which resolved fol-
lowing treatment with an antimicrobial and/or anti-inﬂammatory
60 C. Becskei et al. / Veterinary Parasitology 222 (2016) 56–61
Table 4
Clinical signs of sarcoptic mange. Number (n) and percent (%) of dogs with clinical signs at enrolment and at study completion presented as veterinary patients and dosed
with  sarolaner tablets administered orally or imidacloprid/moxidectin applied topically once a month for two  months.
Clinical sign Sarolaner Imidacloprid/moxidectin
Enrolment n = 53 Completion n = 51 Enrolment n = 26 Completion n = 24
n % n % n % n %
Alopecia 53 100 13 25.5 26 100 4 16.7
Papules 50 94.3 1 2.0 26 100 0 0.0
Erythema 51 96.2 3 5.9 26 100 2 8.3
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Scaling/Crusting 53 100 6 
edication, one dog with pre-renal uraemia, one dog with a
ammary mass and one dog with osteoarthrosis that received anti-
nﬂammatory treatment. In the moxidectin/imidacloprid-treated
roup, there were two dogs with otitis and one dog with herniated
pinal disc. None of these events were considered to be related to
reatment with the test products.
.4. Palatability
Sarolaner chewable tablets were voluntarily and fully consumed
ithin one minute in 90.5% of all 158 occasions they were offered
o primary and supplementary dogs.
. Discussion
One placebo-controlled laboratory study and one multi-center
linical ﬁeld study with a positive control was  conducted to
valuate the efﬁcacy of sarolaner against S. scabiei.  Sarolaner
chieved 100% parasitological cure in both studies following two
onthly administrations and clinical signs of sarcoptic mange
mproved in treated dogs. The efﬁcacy of sarolaner was  non-
nferior to the topically applied positive control in the ﬁeld
tudy; however parasitological cure was not achieved in one
midacloprid/moxidectin-treated dog after two monthly treat-
ents whereas mites were eliminated from all sarolaner-treated
ogs. Sarolaner tablets were also highly palatable with 90.5% accep-
ance by free choice within one minute of offering.
To the authors’ knowledge this is the ﬁrst report to document
omplete parasitological cure of sarcoptic mange in dogs follow-
ng monthly treatment with an oral ectoparasiticide under both
aboratory and ﬁeld conditions. Previously, absence of mites in
kin scrapings has been reported for topical products including
elamectin (Shanks et al., 2000), imidacloprid/moxidectin (Fourie
t al., 2006), and amitraz/ﬁpronil/S-methoprene (Gaxiola et al.,
013) after two monthly administrations in laboratory studies. Par-
sitological cure was not achieved in all dogs after two monthly or
our biweekly administrations of an amitraz/metaﬂumizone spot-
n (Fourie et al., 2007) and after two monthly administration of
yriprole (Fourie et al., 2010). In dogs ﬁtted with an imidaclo-
rid/ﬂumethrin collar, parasitological cure was reported after three
onths in a laboratory study (Stanneck et al., 2012). In a laboratory
tudy with oral milbemycin, the presence of mites in skin scrapings
as not evaluated, but only skin lesions were assessed (Miller et al.,
996), thus these results are difﬁcult to compare with the current
tudy.
Interestingly, in most of the above laboratory studies either no
ontrol group was included (Miller et al., 1996; Fourie et al., 2007;
tanneck et al., 2012) or a positive control product was  used (Fourie
t al., 2006, 2010). In the laboratory studies that used placebo-
reated (Shanks et al., 2000) or untreated control animals (Gaxiola
t al., 2013), a decrease in mite counts was reported in the con-
rol animals during the study period. These results are in line with2.0 25 96.2 3 12.5
11.8 25 96.2 3 12.5
the observations in the placebo-treated animals in the laboratory
study reported here, in which at the end of the study, no mites
were found in the skin scrapings of nine out of the 11 dogs that did
not receive immunosuppression. In contrast, all placebo-treated
dogs that received immunosuppressive treatment from the study
start maintained the mite infestations throughout the study. These
observations suggest that mite counts in laboratory studies may
be biased by spontaneous cure and immunosuppressive treatment
may  be required to evaluate treatment success under laboratory
conditions.
While Sarcoptes mites are notoriously difﬁcult to ﬁnd in skin
scrapings (Miller et al., 2013), the dogs in both studies reported
here were subjected to a high level of scrutiny to detect mites. Each
dog was required to have 10 negative skin scrapings from different
body areas to be declared parasitologically cured, providing a high
level of conﬁdence that these dogs were truly negative for mites.
A similar high level of scrutiny was  only reported in one previous
laboratory study (Shanks et al., 2000) and in a multi-center ﬁeld
study (Six et al., 2000). In another ﬁeld study eight skin scrapings
were collected from each dog (Krieger et al., 2005), while in other
studies only up to ﬁve skin scrapings were done (Fourie et al., 2006,
2007, 2010; Stanneck et al., 2012; Gaxiola et al., 2013).
Randomized, controlled multi-center ﬁeld studies of similar
scale and design have been reported for selamectin (Six et al., 2000)
and for imidacloprid/moxidectin (Krieger et al., 2005). In both of
these studies, complete parasitological cure was  achieved follow-
ing two  monthly treatments in all dogs that was  accompanied by
an improvement in the pruritus and skin lesions characteristic of
sarcoptic mange. In the ﬁeld study reported here, pruritus, the most
prominent clinical sign of sarcoptic mange, resolved in all but one
sarolaner-treated dog (2%) and this dog had only mild pruritus
at study completion. In contrast, in the imidacloprid/moxidectin-
treated group, three dogs (12.5%) had varying degree of mild to
severe pruritus following two  monthly treatments. As pruritus in
sarcoptic mange is thought to be a symptom of a hypersensitivity
reaction to mite antigens, it may  still be observed in dogs several
weeks after parasitological cure because of the presence of the dead
or decomposing mites in the skin following treatment. The day 14
mite count results in the laboratory study and the fact that pruritus
resolved in all but one dog following two monthly treatments in
the ﬁeld study presented here indicates that sarolaner has rapid,
miticidal activity.
The sarolaner tablets (SimparicaTM) were highly palatable in
the target population with over 90% voluntary, full consumption.
Owner non-compliance is reported as a frequent cause of mange
treatment failures (Miller et al., 2013). The high palatability and
ease of administration of these ﬂavored, chewable tablets could
reduce suboptimal efﬁcacy results in dogs with sarcoptic mange
due to non-compliance. This combined with excellent efﬁcacy
against S. scabiei following two  monthly doses will make sarolaner
a valuable tool for veterinarians and dog owners for the treatment
of sarcoptic mange.
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2012. Efﬁcacy of an imidacloprid/ﬂumethrin collar against ﬂeas, ticks, mitesC. Becskei et al. / Veterinary
. Conclusions
Sarolaner administered orally twice at monthly intervals at
he minimum label dosage of 2 mg/kg was safe and achieved
omplete parasitological cure in dogs with natural infestations of
arcoptes scabiei.  In addition, the clinical signs of sarcoptic mange
mproved without topical or systemic concomitant treatment, and
imparicaTM chewable tablets were highly palatable.
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